Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov;39(4):533-46.
doi: 10.1016/j.ucl.2012.07.009. Epub 2012 Sep 4.

Bone-targeted agents: preventing skeletal complications in prostate cancer

Alicia K Morgans  1 , Matthew R Smith
Affiliations
Review

Bone-targeted agents: preventing skeletal complications in prostate cancer

Alicia K Morgans et al. Urol Clin North Am. 2012 Nov.

Abstract

In men, prostate cancer is the most common non-cutaneous malignancy and the second most common cause of cancer death. Skeletal complications occur at various points during the disease course, either due to bone metastases directly, or as an unintended consequence of androgen deprivation therapy (ADT). Bone metastases are associated with pathologic fractures, spinal cord compression, and bone pain and can require narcotics or palliative radiation for pain relief. ADT results in bone loss and fragility fractures. This review describes the biology of bone metastases, skeletal morbidity, and recent advances in bone-targeted therapies to prevent skeletal complications of prostate cancer.

PubMed Disclaimer

References

    1. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. 2010 Based on November 2009 SEER data submission, posted to the SEER web site. http://seer.cancer.gov/csr/1975_2007/
    1. Tannock IF, de Wit R, Berry WR, et al. the TAXI. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. - PubMed
    1. Perylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. - PubMed
    1. Eriksen EF, Colvard DS, Berg NJ, Graham, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 1988;241(4861):84–86. - PubMed
    1. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Research & Therapy. 2007;9(Suppl 1 (S1)) - PMC - PubMed

MeSH terms